retatrutide triple agonist gip glp-1 glucagon phase 2 obesity trial What GLP‑3 Really Is: Triple‑Receptor Drug Retatrutide Dosage & Titration: Complete
Description
Weight regain and cardiometabolic effects after withdrawal of semaglutide: the step 1 trial extension
Christopher McGowan, a gastroenterologist who runs a weight loss clinic in Cary, North Carolina
The findings have begun to shift the conversation from fear toward reassurance
I would be very interested on your take on two things1) the very high discontinuation rate of these drugs (and the corresponding need for a focus on behavior change as an adjuvant/parallel to course of treatment) and, 2) the impact of significant lean muscle and bone loss during treatment w/GLP-1s
